Scancell Holdings plc (AIM:SCLP)
9.75
0.00 (0.00%)
Oct 10, 2025, 5:15 PM GMT+1
Scancell Holdings Revenue
In the fiscal year ending April 30, 2025, Scancell Holdings had annual revenue of 4.71M GBP. Scancell Holdings had revenue of 4.71M in the half year ending April 30, 2025.
Revenue
4.71M
Revenue Growth
n/a
P/S Ratio
21.48
Revenue / Employee
78.52K
Employees
60
Market Cap
101.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2025 | 4.71M | - | - |
Apr 30, 2024 | - | - | - |
Apr 30, 2023 | 5.27M | - | - |
Apr 30, 2022 | - | - | - |
Apr 30, 2021 | - | - | - |
Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Scancell Holdings News
- 4 weeks ago - Scancell Holdings PLC (SCNLF) Full Year 2025 Earnings Call Highlights: Strategic Partnerships ... - GuruFocus
- 4 weeks ago - Full Year 2025 Scancell Holdings PLC Earnings Call Transcript - GuruFocus
- 4 weeks ago - Scancell Holdings Plc (SCNLF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Scancell Holdings plc 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Scancell Holdings plc GAAP EPS of -1.26p, revenue of £4.7M - Seeking Alpha
- 4 weeks ago - Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 - GlobeNewsWire
- 2 months ago - Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ - GlobeNewsWire
- 1 year ago - PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma - Business Wire